NZ595569A - Substituted 3-amino-2-mercaptoquinolines as kcnq2/3 modulators - Google Patents
Substituted 3-amino-2-mercaptoquinolines as kcnq2/3 modulatorsInfo
- Publication number
- NZ595569A NZ595569A NZ595569A NZ59556910A NZ595569A NZ 595569 A NZ595569 A NZ 595569A NZ 595569 A NZ595569 A NZ 595569A NZ 59556910 A NZ59556910 A NZ 59556910A NZ 595569 A NZ595569 A NZ 595569A
- Authority
- NZ
- New Zealand
- Prior art keywords
- quinolin
- mercaptoquinolines
- kcnq2
- modulators
- amino
- Prior art date
Links
- WPFIJUWKLJCQOO-UHFFFAOYSA-N 3-amino-1h-quinoline-2-thione Chemical class C1=CC=C2NC(=S)C(N)=CC2=C1 WPFIJUWKLJCQOO-UHFFFAOYSA-N 0.000 title 1
- KXZSVYHFYHTNBI-UHFFFAOYSA-N 1h-quinoline-2-thione Chemical class C1=CC=CC2=NC(S)=CC=C21 KXZSVYHFYHTNBI-UHFFFAOYSA-N 0.000 abstract 1
- NBQOMSWDPMGLDV-UHFFFAOYSA-N 3-cyclopentyl-n-(2-ethylsulfanylquinolin-3-yl)propanamide Chemical compound CCSC1=NC2=CC=CC=C2C=C1NC(=O)CCC1CCCC1 NBQOMSWDPMGLDV-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000012661 Dyskinesia Diseases 0.000 abstract 1
- 208000014094 Dystonic disease Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000010118 dystonia Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- KGKPFBQUXFOPTK-UHFFFAOYSA-N n-(2-ethylsulfanylquinolin-3-yl)-3,3-dimethylbutanamide Chemical compound C1=CC=C2C=C(NC(=O)CC(C)(C)C)C(SCC)=NC2=C1 KGKPFBQUXFOPTK-UHFFFAOYSA-N 0.000 abstract 1
- IXKMHPRESURQPN-UHFFFAOYSA-N n-[2-[2-(benzenesulfonyl)ethylsulfanyl]quinolin-3-yl]-2-cyclohexylacetamide Chemical compound C=1C2=CC=CC=C2N=C(SCCS(=O)(=O)C=2C=CC=CC=2)C=1NC(=O)CC1CCCCC1 IXKMHPRESURQPN-UHFFFAOYSA-N 0.000 abstract 1
- IWQRREJPCILBIR-UHFFFAOYSA-N n-[2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)quinolin-3-yl]-2-thiophen-2-ylacetamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1NC(=O)CC1=CC=CS1 IWQRREJPCILBIR-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09003431 | 2009-03-10 | ||
| PCT/EP2010/001449 WO2010102779A1 (de) | 2009-03-10 | 2010-03-09 | Substituierte 3-amino-2-mercaptochinoline als kcnq2/3 modulatoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ595569A true NZ595569A (en) | 2012-11-30 |
Family
ID=40591941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ595569A NZ595569A (en) | 2009-03-10 | 2010-03-09 | Substituted 3-amino-2-mercaptoquinolines as kcnq2/3 modulators |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8207342B2 (enExample) |
| EP (1) | EP2406228B1 (enExample) |
| JP (1) | JP5727945B2 (enExample) |
| KR (1) | KR20110130461A (enExample) |
| CN (1) | CN102341374A (enExample) |
| AR (1) | AR075730A1 (enExample) |
| AU (1) | AU2010223556B2 (enExample) |
| BR (1) | BRPI1009519A2 (enExample) |
| CA (1) | CA2754943A1 (enExample) |
| CL (1) | CL2011002160A1 (enExample) |
| CO (1) | CO6410291A2 (enExample) |
| EC (1) | ECSP11011346A (enExample) |
| ES (1) | ES2436365T3 (enExample) |
| IL (1) | IL214944A0 (enExample) |
| MX (1) | MX2011009338A (enExample) |
| NZ (1) | NZ595569A (enExample) |
| PE (1) | PE20120535A1 (enExample) |
| PL (1) | PL2406228T3 (enExample) |
| RU (1) | RU2011140701A (enExample) |
| TW (1) | TWI504395B (enExample) |
| WO (1) | WO2010102779A1 (enExample) |
| ZA (1) | ZA201107370B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1009428A2 (pt) * | 2009-03-10 | 2016-03-01 | Gruenenthal Gmbh | 3-aminoisoxazolopiridina substituída como moduladores de kcnq2/3 |
| TW201038565A (en) | 2009-03-12 | 2010-11-01 | Gruenenthal Gmbh | Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators |
| TWI461197B (zh) | 2009-03-12 | 2014-11-21 | 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier | |
| TWI475020B (zh) | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
| RU2595894C2 (ru) | 2010-08-27 | 2016-08-27 | Грюненталь Гмбх | Замещенные 2-окси-хинолин-3-карбоксамиды в качестве модуляторов kcnq2/3 |
| TW201211007A (en) | 2010-08-27 | 2012-03-16 | Gruenenthal Gmbh | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators |
| HUE024870T2 (en) | 2010-08-27 | 2016-02-29 | Gruenenthal Gmbh | Substituted 2-oxo and 2-thioxo-dihydroquinoline-3-carboxamides as modulators of KCNQ2 / 3 |
| MX2013002295A (es) | 2010-09-01 | 2013-05-09 | Gruenenthal Gmbh | 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. |
| DE102018212006B3 (de) * | 2018-07-18 | 2019-10-31 | Universität Greifswald | Thioether als Modulatoren von Kv7.2/Kv7.3-Kanälen |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2706977A1 (de) | 1977-02-18 | 1978-08-24 | Hoechst Ag | Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung |
| FR2532939A1 (fr) | 1982-09-13 | 1984-03-16 | Roussel Uclaf | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus |
| DE4032147A1 (de) | 1990-10-10 | 1992-04-16 | Bayer Ag | Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung |
| US5583147A (en) * | 1994-03-23 | 1996-12-10 | The Dupont Merck Pharmaceutical Company | Amides for the treatment of atherosclerosis |
| EP0716077A1 (de) | 1994-12-08 | 1996-06-12 | Ciba-Geigy Ag | Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren |
| WO1996026925A1 (en) | 1995-03-01 | 1996-09-06 | Banyu Pharmaceutical Co., Ltd. | Arylthioacetamide derivatives |
| CA2301549A1 (en) * | 1997-08-28 | 1999-03-04 | Piyasena Hewawasam | 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators |
| DE19738616A1 (de) | 1997-09-04 | 1999-03-11 | Clariant Gmbh | 4-Hydroxychinolin-3-carbonsäure-Derivate als Lichtschutzmittel |
| WO2000042026A1 (en) | 1999-01-15 | 2000-07-20 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
| EP1208085B1 (en) | 1999-08-04 | 2007-12-05 | Icagen, Inc. | Benzanilides as potassium channel openers |
| JP2003506388A (ja) | 1999-08-04 | 2003-02-18 | アイカゲン インコーポレイテッド | 疼痛および不安症を処置または予防するための方法 |
| JP2005507853A (ja) | 2001-02-20 | 2005-03-24 | ブリストル−マイヤーズ スクイブ カンパニー | Ｋｃｎｑカリウムチャンネルモジュレーター並びに片頭痛および機構的に関連する疾患の治療におけるそれらの使用 |
| EP1361879A1 (en) | 2001-02-20 | 2003-11-19 | Bristol-Myers Squibb Company | 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators |
| US6593349B2 (en) | 2001-03-19 | 2003-07-15 | Icagen, Inc. | Bisarylamines as potassium channel openers |
| EP1372654A4 (en) | 2001-04-06 | 2007-10-03 | Smithkline Beecham Corp | QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES |
| AU2003272552A1 (en) | 2002-09-17 | 2004-04-08 | Pharmacia Corporation | Aromatic liver x-receptor modulators |
| JP4652816B2 (ja) | 2002-12-23 | 2011-03-16 | アイシーエージェン インコーポレイテッド | カリウムチャネルモジュレータとしてのキナゾリノン |
| EP1449841A1 (en) | 2003-02-19 | 2004-08-25 | Bayer CropScience SA | New fungicidal compounds |
| EP1680411A2 (en) | 2003-10-08 | 2006-07-19 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups |
| EP1756043B1 (en) | 2004-05-04 | 2009-07-01 | RaQualia Pharma Inc | Ortho substituted aryl or heteroaryl amide compounds |
| JP2008519814A (ja) | 2004-11-12 | 2008-06-12 | ガラパゴス・ナムローゼ・フェンノートシャップ | プロテインキナーゼ酵素の活性部位と結合する窒素複素環式芳香族化合物 |
| PL2298766T3 (pl) | 2005-03-03 | 2014-09-30 | H Lundbeck As | Preparaty farmaceutyczne zawierające podstawione pochodne pirydyny |
| DE102005038947A1 (de) | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
| ATE432259T1 (de) | 2005-07-20 | 2009-06-15 | Lilly Co Eli | Pyridinderivate als dipeptedyl-peptidase-hemmer |
| EP1922311A2 (en) | 2005-09-09 | 2008-05-21 | Brystol-Myers Squibb Company | Acyclic ikur inhibitors |
| WO2007057447A1 (en) * | 2005-11-18 | 2007-05-24 | Neurosearch A/S | Novel quinazoline derivatives and their medical use |
| ES2338278T3 (es) | 2006-07-20 | 2010-05-05 | Amgen Inc. | Derivados de benzo(d)isoxazol como inhibidores de c-kit tirosina quinasa para el tratamiento de enfermedades asociadas con la sobreproduccion de histamina. |
| WO2008011110A2 (en) | 2006-07-20 | 2008-01-24 | Amgen Inc. | Di-amino-substituted heterocyclic compounds and methods of use |
| WO2008012532A2 (en) | 2006-07-27 | 2008-01-31 | Astrazeneca Ab | : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase |
| DE102006049452A1 (de) | 2006-10-17 | 2008-05-08 | Grünenthal GmbH | Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln |
| US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
| BRPI0814758A2 (pt) | 2007-08-03 | 2015-03-03 | Hoffmann La Roche | Piridinacarboxamida e derivados de benzamida como ligantes taar1 |
| US8299123B2 (en) | 2007-10-19 | 2012-10-30 | Boehringer Ingelheim International Gmbh | CCR10 antagonists |
| BRPI1009428A2 (pt) | 2009-03-10 | 2016-03-01 | Gruenenthal Gmbh | 3-aminoisoxazolopiridina substituída como moduladores de kcnq2/3 |
| TW201038565A (en) | 2009-03-12 | 2010-11-01 | Gruenenthal Gmbh | Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators |
| TWI475020B (zh) | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
| TWI461197B (zh) | 2009-03-12 | 2014-11-21 | 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier |
-
2010
- 2010-03-03 TW TW099106075A patent/TWI504395B/zh not_active IP Right Cessation
- 2010-03-09 NZ NZ595569A patent/NZ595569A/xx not_active IP Right Cessation
- 2010-03-09 PL PL10708503T patent/PL2406228T3/pl unknown
- 2010-03-09 WO PCT/EP2010/001449 patent/WO2010102779A1/de not_active Ceased
- 2010-03-09 CN CN2010800109786A patent/CN102341374A/zh active Pending
- 2010-03-09 MX MX2011009338A patent/MX2011009338A/es active IP Right Grant
- 2010-03-09 CA CA2754943A patent/CA2754943A1/en not_active Abandoned
- 2010-03-09 ES ES10708503T patent/ES2436365T3/es active Active
- 2010-03-09 RU RU2011140701/04A patent/RU2011140701A/ru not_active Application Discontinuation
- 2010-03-09 AU AU2010223556A patent/AU2010223556B2/en not_active Ceased
- 2010-03-09 EP EP10708503.7A patent/EP2406228B1/de not_active Not-in-force
- 2010-03-09 KR KR1020117023698A patent/KR20110130461A/ko not_active Withdrawn
- 2010-03-09 PE PE2011001564A patent/PE20120535A1/es not_active Application Discontinuation
- 2010-03-09 BR BRPI1009519A patent/BRPI1009519A2/pt not_active IP Right Cessation
- 2010-03-09 JP JP2011553339A patent/JP5727945B2/ja not_active Expired - Fee Related
- 2010-03-10 US US12/720,770 patent/US8207342B2/en not_active Expired - Fee Related
- 2010-03-10 AR ARP100100719A patent/AR075730A1/es not_active Application Discontinuation
-
2011
- 2011-08-12 CO CO11102966A patent/CO6410291A2/es not_active Application Discontinuation
- 2011-09-02 CL CL2011002160A patent/CL2011002160A1/es unknown
- 2011-09-04 IL IL214944A patent/IL214944A0/en unknown
- 2011-09-23 EC EC2011011346A patent/ECSP11011346A/es unknown
- 2011-10-07 ZA ZA2011/07370A patent/ZA201107370B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO6410291A2 (es) | 2012-03-30 |
| ZA201107370B (en) | 2012-07-25 |
| ES2436365T3 (es) | 2013-12-30 |
| BRPI1009519A2 (pt) | 2016-03-15 |
| EP2406228B1 (de) | 2013-09-18 |
| CL2011002160A1 (es) | 2012-08-17 |
| IL214944A0 (en) | 2011-11-30 |
| PE20120535A1 (es) | 2012-05-09 |
| TW201036610A (en) | 2010-10-16 |
| AU2010223556B2 (en) | 2015-01-29 |
| CN102341374A (zh) | 2012-02-01 |
| PL2406228T3 (pl) | 2014-02-28 |
| RU2011140701A (ru) | 2013-04-20 |
| JP5727945B2 (ja) | 2015-06-03 |
| TWI504395B (zh) | 2015-10-21 |
| WO2010102779A1 (de) | 2010-09-16 |
| CA2754943A1 (en) | 2010-09-16 |
| ECSP11011346A (es) | 2011-10-31 |
| US20100234421A1 (en) | 2010-09-16 |
| EP2406228A1 (de) | 2012-01-18 |
| AR075730A1 (es) | 2011-04-20 |
| KR20110130461A (ko) | 2011-12-05 |
| JP2012521966A (ja) | 2012-09-20 |
| AU2010223556A1 (en) | 2011-11-03 |
| US8207342B2 (en) | 2012-06-26 |
| MX2011009338A (es) | 2011-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ595569A (en) | Substituted 3-amino-2-mercaptoquinolines as kcnq2/3 modulators | |
| NZ595625A (en) | Substituted 2-mercaptoquinoline-3-carboxamides as kcnq2/3 modulators | |
| MX344308B (es) | Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso. | |
| ATE528002T1 (de) | Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden | |
| ATE540941T1 (de) | 1-ä2-(2,4-dimethylphenylsulfanyl)phenylüpiperaz n als verbindung mit kombinierter serotoninwiederaufnahme-, 5-ht3- und 5-ht1a- aktivität zur behandlung kognitiver störungen | |
| DE602004022974D1 (de) | Tricyclische hydroxamat- und benzamidderivate, zusammensetzungen und verfahren | |
| PH12012501492B1 (en) | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | |
| NZ593994A (en) | Substituted 4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as kcnq2/3 modulators | |
| SG179410A1 (en) | Therapeutic uses of inhibitors of rtp801 | |
| MX2014003408A (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1). | |
| WO2006023544A3 (en) | Therapeutic uses of inhibitors of rtp801 | |
| BR112015001847A2 (pt) | composições e tratamento para doenças e distúrbios nos olhos | |
| MX2009012608A (es) | Compuestos de hidroxietil amina substituidos como moduladores de beta-secretasa y metodos de uso. | |
| WO2008050341A3 (en) | Novel psychotropic agents having glutamate nmda activity | |
| EP2604602A4 (en) | HETEROARYL PYRAZOLE DERIVATIVE | |
| NZ595627A (en) | Substituted 2-mercapto-3-aminopyridines as kcnq2/3 modulators | |
| WO2007087424A3 (en) | Method of treating kcnq related disorders using organozinc compounds | |
| NZ604745A (en) | Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators | |
| WO2008099887A1 (ja) | メチル ｎ－［３－（６，７－ジメトキシ－２－メチルアミノキナゾリン－４－イル）フェニル］テレフタラミックアシッドの結晶、非晶質体または塩 | |
| EA200601449A1 (ru) | Применение агомелатина для получения лекарственных средств, предназначенных для лечения нарушений сна у пациента с депрессией | |
| MY148880A (en) | N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression | |
| IL179924A0 (en) | 2 - (1h-indolylsulfanyl) - aryl amine derivatives for use in the treatment of affective disorders, pain adhd and stress urinary incontinence | |
| WO2009134668A3 (en) | 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators | |
| EA200970044A1 (ru) | Производные пирролидина, обладающие активностью в отношении транспортера glyt1 | |
| IL164779A0 (en) | Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other oculat disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |